EMI (Encore Medical) DeferredTaxAndRevenue: $0.07 Mil (As of Dec. 2025)


What is Encore Medical DeferredTaxAndRevenue?

Encore Medical EMI DeferredTaxAndRevenue is $0.07 Mil as of Dec. 2025.

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Encore Medical's current deferred tax and revenue for the quarter that ended in Dec. 2025 was $0.07 Mil.

Encore Medical DeferredTaxAndRevenue Related Terms

Encore Medical DeferredTaxAndRevenue Historical Data

* Premium members only.

The historical data trend for Encore Medical's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Encore Medical DeferredTaxAndRevenue Chart

Encore Medical Annual Data
Trend Dec23 Dec24 Dec25
DeferredTaxAndRevenue
0.00 0.00 0.07

Encore Medical Quarterly Data
Dec23 Sep24 Dec24 Jun25 Sep25 Dec25
DeferredTaxAndRevenue Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.07
Frequently Asked Questions Learn more about DeferredTaxAndRevenue →
What does a DeferredTaxAndRevenue of $0.07 Mil mean?
Encore Medical (EMI) has a DeferredTaxAndRevenue of $0.07 Mil as of Dec. 2025. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Encore Medical.
Is Encore Medical's DeferredTaxAndRevenue too high?
Encore Medical's current DeferredTaxAndRevenue is $0.07 Mil.
How does Encore Medical's DeferredTaxAndRevenue compare to ?
Encore Medical's DeferredTaxAndRevenue of $0.07 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good DeferredTaxAndRevenue for a Medical Devices & Instruments company?
A good DeferredTaxAndRevenue depends on the Medical Devices & Instruments industry context. However, DeferredTaxAndRevenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high DeferredTaxAndRevenue mean?
A high DeferredTaxAndRevenue can signal that a stock is expensive relative to its fundamentals. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Encore Medical. Encore Medical's current DeferredTaxAndRevenue is $0.07 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Encore Medical stock overvalued right now?
Encore Medical (EMI) has a current DeferredTaxAndRevenue of $0.07 Mil. The current DeferredTaxAndRevenue is $0.07 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is DeferredTaxAndRevenue calculated?
DeferredTaxAndRevenue is calculated from a company's financial statements. For Encore Medical (EMI), the current DeferredTaxAndRevenue is $0.07 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Encore Medical Business Description

Comparable Companies
Address 2975 Lone Oak Drive, Suite 140, Eagan, MN, USA, 55121
Encore Medical Inc develops, manufactures, and markets septal occlusion devices for the repair of certain cardiac defects. Its products have been implanted in approximately 35,000 patients outside the United States. Its closure device is designed to correct a cardiac defect, generally diagnosed in adulthood, known as a patent foramen ovale (PFO). The company also currently market and sell septal occlusion devices for the transcatheter closure of atrial septal defects (ASD).